This is the authors' abstract. We don't add key points for this paper.
Loretta J. Nastoupila*, Sattva S. Neelapua, Richard Eric Davisa, Felipe Samaniegoa, Nathan H. Fowlera , Jason Westina , Hun Ju Leea, Michael Wanga , Fredrick Hagemeistera, Alexander R. L. Cecilb, James Dowb, Kemal Haqueb, Franck A. Silvab, Andrew Whaleb, Letitia Lensunb, Elisabeth A. Boneb, Hilary McElwaine-Johnnb & Philip A. Beerb* a Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USAb Karus Therapeutics Ltd., Harwell, UKSupplemental data for this article can be accessed here.CONTACT Loretta J. Nastoupil LNastoupil@mdanderson.org Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPhilip A. Beer P.Beer@karustherapeutics.com Karus Therapeutics Ltd., Genesis Building, Library Avenue, Harwell Campus, Oxfordshire OX11 0SG, UKAbstractPI3-kinase p110δ is mainly expressed in lymphocytes and is an attractive therapeutic target in B cell lymphomas. Targeting p110β may further suppress tumor growth and overcome escape mechanisms. KA2237 is an oral, potent, dual p110β/p110δ inhibitor. In preclinical studies, KA2237 inhibited p110β- and p110δ-dependent AKT activation and suppressed proliferation of diverse hematological and epithelial tumors. Twenty-one patients received KA2237 in a first-in-human phase I study (NCT02679196; diffuse large B cell, n = 8; follicular, n = 5; mantle cell, n = 3; chronic lymphocytic leukemia/small lymphocytic lymphoma, n = 3; marginal zone, n = 1; Waldenstrom’s, n = 1). Median age 69; median prior therapies 3. Eighty-six percent of patients experienced treatment-related adverse events (TRAEs). Forty-three percent of patients experienced grade ≥3 TRAEs, with rash (n = 3), pneumonia (n = 3), transaminitis (n = 2), and pneumonitis (n = 2) being most common. Thirty-three percent discontinued treatment due to adverse events. KA2237 induced objective responses in indolent and aggressive lymphoma (overall response rate 37%; complete response n = 4, partial response n = 3).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nastoupil et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: